Andrea Apolo
#62,784
Most Influential Person Now
American medical oncologist
Andrea Apolo's AcademicInfluence.com Rankings
Andrea Apolophilosophy Degrees
Philosophy
#9024
World Rank
#12516
Historical Rank
Logic
#8431
World Rank
#10548
Historical Rank
Download Badge
Philosophy
Andrea Apolo's Degrees
- Bachelors Biology University of Miami
Similar Degrees You Can Earn
Why Is Andrea Apolo Influential?
(Suggest an Edit or Addition)According to Wikipedia, Andrea B. Apolo is an American medical oncologist specialized in bladder cancer research. She is an investigator in the National Cancer Institute's genitourinary malignancies branch and head of the bladder cancer section.
Andrea Apolo's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. (2021) (566)
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study (2017) (495)
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. (2018) (438)
- Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. (2010) (141)
- Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer* (2008) (137)
- Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. (2013) (96)
- 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial (2020) (89)
- Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. (2013) (80)
- Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer (2016) (78)
- The Kinetics and Reproducibility of 18F-Sodium Fluoride for Oncology Using Current PET Camera Technology (2012) (67)
- Multimodal management of muscle-invasive bladder cancer. (2014) (66)
- Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer (2019) (64)
- Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors (2020) (60)
- Repeatability of Quantitative 18F-NaF PET: A Multicenter Study (2016) (60)
- Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. (2018) (57)
- Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy. (2012) (48)
- A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer (2015) (48)
- Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. (2014) (48)
- Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone. (2017) (46)
- Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial. (2016) (46)
- Advances in medical imaging for the diagnosis and management of common genitourinary cancers. (2017) (45)
- Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions (2014) (44)
- Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. (2020) (42)
- Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. (2014) (42)
- Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies (2019) (41)
- A Phase II Clinical Trial of TRC105 (Anti‐Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma (2017) (41)
- Magnetic Nanoparticle Mediated Steroid Delivery Mitigates Cisplatin Induced Hearing Loss (2017) (41)
- Targeted therapies in urothelial carcinoma (2014) (40)
- Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. (2021) (40)
- Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. (2020) (40)
- Immunotherapy: a new treatment paradigm in bladder cancer (2017) (40)
- Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. (2015) (39)
- Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma (2017) (38)
- Trimodality therapy in bladder cancer: who, what, and when? (2015) (38)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression. (2016) (37)
- Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. (2019) (37)
- Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis (2020) (37)
- Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. (2012) (36)
- A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. (2017) (35)
- Large‐scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival (2019) (34)
- Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study. (2017) (33)
- Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (2016) (33)
- Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer (2019) (31)
- Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial. (2017) (30)
- Anti–Programmed Cell Death 1/Ligand 1 (PD‐1/PD‐L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development (2017) (29)
- Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient Survival (2019) (29)
- Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. (2022) (28)
- Emerging immunotherapies for bladder cancer (2015) (27)
- The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents (2016) (27)
- Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report (2018) (26)
- A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER). (2018) (25)
- Genetic Variant as a Selection Marker for Anti–Prostate Stem Cell Antigen Immunotherapy of Bladder Cancer (2012) (25)
- A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC). (2011) (24)
- Consistency and efficiency of CT analysis of metastatic disease: semiautomated lesion management application within a PACS. (2013) (22)
- The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. (2014) (21)
- A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC) (2016) (20)
- Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. (2015) (20)
- Imaging muscle-invasive and metastatic urothelial carcinoma (2015) (19)
- New and promising strategies in the management of bladder cancer. (2015) (19)
- 846OFinal results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies (2017) (18)
- A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors (2016) (18)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible (2016) (17)
- Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder (2014) (17)
- Immunotherapies for bladder cancer: a new hope (2015) (16)
- Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC). (2012) (16)
- Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC). (2019) (16)
- SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer (2018) (16)
- PDL1: The Illusion of an Ideal Biomarker. (2016) (15)
- Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. (2014) (15)
- Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI). (2018) (15)
- Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. (2022) (14)
- A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (14)
- Contemporary Patterns of Multidisciplinary Care in Patients With Muscle‐invasive Bladder Cancer (2018) (14)
- Rapid development of migratory, linear, and serpiginous lesions in association with immunosuppression. (2014) (13)
- Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder (2014) (13)
- Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma (2018) (13)
- Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial. (2021) (13)
- Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation. (2019) (13)
- Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis (2020) (13)
- Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors (2022) (12)
- Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer. (2014) (12)
- 856PAvelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with ≥6 months of follow-up in all patients (2017) (12)
- 18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab (2019) (11)
- Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. (2020) (11)
- Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer. (2015) (11)
- Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. (2022) (11)
- Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer (2020) (10)
- A phase I study of TRC 105 anti-endoglin ( CD 105 ) antibody in metastatic castration-resistant prostate cancer (2015) (9)
- Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma (2016) (9)
- Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (9)
- Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. (2019) (9)
- Management of Adverse Events Associated with Cabozantinib Plus Nivolumab in Renal Cell Carcinoma: A Review (2021) (9)
- Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival (2022) (9)
- A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. (2013) (9)
- A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG. (2014) (9)
- Radiology Reports With Hyperlinks Improve Target Lesion Selection and Measurement Concordance in Cancer Trials. (2017) (9)
- Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors. (2021) (8)
- Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (8)
- Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. (2021) (8)
- A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). (2014) (8)
- Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer (2017) (8)
- Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. (2015) (8)
- 18F-FDG PET-MRI in the management of muscle invasive bladder cancer: Challenges in imaging and solutions (2016) (8)
- Clinical states model for biomarkers in bladder cancer. (2009) (8)
- ENABLE (Exportable Notation and Bookmark List Engine): an Interface to Manage Tumor Measurement Data from PACS to Cancer Databases (2017) (7)
- Efficacy and immune-related adverse event associations in avelumab-treated patients (2020) (7)
- Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature (2019) (7)
- Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer (2018) (7)
- Assessing Contemporary Trends in Female Speakership within Urologic Oncology. (2020) (7)
- Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research. (2013) (7)
- Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. (2019) (6)
- Examining the management of muscle-invasive bladder cancer (MIBC) by medical oncologists (MO). (2012) (6)
- A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy. (2014) (6)
- Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop (2021) (6)
- Vascular thromboembolic events in patients (pts) with advanced urothelial cancer (UC) treated with carboplatin/gemcitabine alone or in combination with bevacizumab. (2009) (6)
- Predicting cancer immunotherapy response from gut microbiomes using machine learning models (2022) (6)
- Phase II trial of gemcitabine, carboplatin, and bevacizumab in chemotherapy-naive patients (Pts) with advanced/metastatic urothelial carcinoma (UC). (2011) (5)
- Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma. (2014) (5)
- Targeting the Epidermal Growth Factor Receptor in Bladder Cancer (2013) (5)
- Cabozantinib for the treatment of solid tumors: a systematic review (2022) (5)
- Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy (2022) (5)
- Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up. (2019) (5)
- 2630 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic urothelial carcinoma: A phase Ib trial (2015) (4)
- Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder (2020) (4)
- Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells. (2017) (4)
- Systemic therapy in bladder preservation. (2020) (4)
- Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC). (2011) (4)
- Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER. (2022) (4)
- Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome (2022) (4)
- Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma. (2016) (3)
- New facial papules in a 66-year-old woman with bladder cancer. (2014) (3)
- MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays (2022) (3)
- Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma (2023) (3)
- A phase II study of trebananib (AMG 386) and abiraterone in metastatic castration resistant prostate cancer. (2014) (3)
- MP16-14 CLINICAL OUTCOMES OF A RANDOMIZED, PROSPECTIVE, PHASE II STUDY TO DETERMINE THE EFFICACY OF BACILLUS CALMETTE-GUERIN (BCG) GIVEN IN COMBINATION WITH PANVAC VERSUS BCG GIVEN ALONE IN ADULTS WITH HIGH GRADE BCG-REFRACTORY NON-MUSCLE INVASIVE BLADDER CANCER (2021) (3)
- 5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors. (2019) (3)
- 663P First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial (2021) (3)
- CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1. (2021) (3)
- Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC). (2021) (3)
- Determining superior first-line therapy in metastatic bladder cancer (2019) (3)
- Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. (2022) (3)
- Targeting molecular aberrations in urothelial carcinoma: are we almost there? (2013) (3)
- Temporal characterization of F-18 NaF PET/CT uptake (2011) (3)
- MO-AB-BRA-05: [18F]NaF PET/CT Imaging Biomarkers in Metastatic Prostate Cancer. (2016) (3)
- COXEN prediction of antineoplastic drug sensitivity in bladder cancer patients. (2015) (3)
- Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer. (2020) (3)
- Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma. (2022) (3)
- A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (2)
- Exploring multidisciplinary practice patterns in the management of muscle invasive bladder cancer (MIBC) across the U.S. and Canada in 2015. (2016) (2)
- Assessing tumor response using CT density-volume trajectory in metastatic bladder cancer. (2014) (2)
- A precision, personalized approach to the management of bladder cancer. (2015) (2)
- A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2014) (2)
- Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi). (2020) (2)
- Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy. (2020) (2)
- Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy (2020) (2)
- A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (2)
- 456 Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy (2020) (2)
- Abstract 2217: Serum metabolic profiling identified a distinct metabolic signature in bladder cancer smokers: A key metabolic enzymes associated with patient survival (2019) (1)
- A pilot study on the clinical value of 18F-sodium fluoride PET/CT in advanced prostate cancer. (2012) (1)
- Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations in metastatic castrate resistant prostate cancer (mCRPC). (2013) (1)
- Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder (2014) (1)
- Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (1)
- Peripheral-blood gene expression profiling in bladder cancer (BC) patients (pts) (2008) (1)
- Tumor regression and growth rates determined in two intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. (2012) (1)
- Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2011) (1)
- Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer. (2019) (1)
- A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies. (2021) (1)
- Preliminary results of a prospective study of 18F-NAF PET/CT in prostate cancer. (2013) (1)
- 664P Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors (2021) (1)
- A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC). (2013) (1)
- Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations. (2013) (1)
- The high incidence of vascular thromboembolic events (VTE) in advanced urothelial cancer (UC) patients (pts) treated with carboplatin (Cb): Analysis of treatment with gemcitabine (G)/cb (GCb), gcb/bevacizumab (GCbBev), or gemcitabine/cisplatin (GCis). (2014) (1)
- ENLIGHT: Pancancer response prediction to targeted and immunotherapies via tumor transcriptomics. (2022) (1)
- Cabozantinib combination therapy for the treatment of solid tumors: a systematic review (2022) (1)
- Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer. (2021) (1)
- Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi). (2019) (1)
- Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC). (2021) (1)
- Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial. (2022) (1)
- A pilot clinical trial of genomic-based therapy assignment with co-expression extrapolation (COXEN) in advanced/metastatic urothelial carcinoma. (2021) (0)
- Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2017) (0)
- Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma. (2014) (0)
- Assessment of treatment response using Computed Tomography (CT) tumor volume measurements and lesion number in metastatic urothelial carcinoma (mUC) patients (pts) receiving cabozantinib. (2015) (0)
- Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT). (2023) (0)
- We were pleased that our commentary "Everything Old is New Again! Neoadjuvant Chemotherapy in the Treatment of Muscle- (2014) (0)
- Met signaling in urothelial carcinoma of the bladder. (2014) (0)
- Patient and caregiver benefit-risk preferences for treatment in advanced urothelial carcinoma. (2020) (0)
- PD51-03 DIGITAL PATHOLOGY OF CIRCULATING TUMOR CELLS WITH MORPHOLOGIC ANALYSIS IS FEASIBLE IN LOCALIZED BLADDER CANCER (2020) (0)
- Erratum: Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemothery (Journal of the National Cancer Institute (2013) 105:7 (499-503)) (2014) (0)
- Evaluation of a new circulating tumor cell (CTC) platform to predict response and survival in metastatic urothelial carcinoma (UC) patients receiving cabozantinib (cabo). (2015) (0)
- Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review. (2023) (0)
- Chemotherapy for metastatic bladder cancer (2015) (0)
- MP49-03 CIRCULATING TUMOR CELL SUBTYPES AND BASELINE T-CELL POPULATION AS PROGNOSTIC BIOMARKERS TO COMBINATION THERAPY WITH CABOZANTINIB, NIVOLUMAB, AND IPILIMUMAB IN METASTATIC GENITOURINARY CANCER PATIENTS (2020) (0)
- [18F]NaF PET/CT imaging biomarkers of progression-free survival in metastatic prostate cancer. (2016) (0)
- The association of FDG PET/CT and NaF PET/CT with survival outcomes in patients (pts) with metastatic genitourinary malignancies (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo +/- Ipi). (2022) (0)
- Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. (2014) (0)
- MPA PASS Enables Stitched Multiplex Multi-Dimensional EV Repertoire Analysis (2021) (0)
- Examining the management of muscle-invasive bladder cancer (MIBC) by medical oncologists (MO). (2012) (0)
- Abstract 2048: Pharmacodynamic biomarker studies of TRC105 anti-endoglin (CD105) antibody revealed anti-angiogenic activity associated with CD105 depletion (2016) (0)
- Impact of anatomic location of bone metastases on prognosis in mCRPC (2020) (0)
- F18-Sodium fluoride PET/CT for metastatic burden quantification in prostate cancer (2012) (0)
- Understanding drivers of treatment preferences in locally advanced or metastatic urothelial carcinoma: A qualitative interview study with patients, caregivers, and physicians. (2023) (0)
- A phase I study of gemcitabine, carboplatin, and lenalidomide for treatment of patients with advanced/metastatic urothelial carcinoma (UC) and other solid tumors. (2014) (0)
- Avelumab treatment in metastatic urothelial carcinoma: Association between early response and durable outcomes in the phase Ib JAVELIN Solid Tumor Study. (2019) (0)
- Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2015) (0)
- Abstract 140: Oncogenic signaling by MET and other cabozantinib targets in cells derived from urothelial carcinoma of the bladder (2015) (0)
- Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer A C (2021) (0)
- Assessment of bone metastases in patients (pts) with urothelial carcinoma using 18F-sodium fluoride PET/CT (18F-NaF) versus 18F-fluorodeoxyglucose PET/CT (18F-FDG). (2014) (0)
- Rapidly Progressing Urothelial Carcinoma Due to a Rare TP53 (p.Arg110Pro) Mutation: A Case Report and Review of the Literature (2021) (0)
- Avelumab treatment in metastatic urothelial carcinoma: Post-hoc analysis of high-risk populations in the phase Ib JAVELIN Solid Tumor Study. (2019) (0)
- New Era of Bladder Cancer Treatments Has Begun (2015) (0)
- Function and Aggressive Disease The 19 q 12 Bladder Cancer GWAS Signal : Association with Cyclin E Updated (2014) (0)
- Integrating chemotherapy and radiotherapy for bladder cancer (2015) (0)
- 18F-FDG-PET/CT imaging to assess response to treatment with cabozantinib at 4 weeks versus 8 weeks of therapy in patients (pts) with metastatic urothelial carcinoma (mUC). (2017) (0)
- Multi-center, retrospective study of first-line systemic therapy ± immune checkpoint inhibition for metastatic neuroendocrine carcinoma of the urinary tract. (2023) (0)
- Abstract 957: Prediction of patient response to targeted and immunotherapies from the tumor transcriptome in a wide set of indications and clinical trials (2023) (0)
- Medical oncologists’ first-line treatment preferences in metastatic urothelial carcinoma. (2020) (0)
- Abstract 4670: Characterization of Met signaling in urothelial cancer of the bladder (2014) (0)
- Feasibility of digital pathology of circulating tumor cells with morphologic analysis in localized bladder cancer. (2020) (0)
- MP68-17 NOVEL INTRAVESICAL THERAPIES IDENTIFIED FROM HIGH THROUGHPUT SCREENING (2015) (0)
- Combined FDG and NaF PET/CT study in patients (pts) with metastatic genitourinary tumors (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo+/-Ipi). (2017) (0)
- Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer (2018) (0)
- Assessing bone response to cabozantinib in patients (pts) with metastatic urothelial carcinoma (mUC) using 18F-Sodium Fluoride (NaF) PET/CT. (2017) (0)
- A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2012) (0)
- Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors. (2019) (0)
- Signaling by Met and related receptor tyrosine kinases in urothelial carcinoma of the bladder. (2015) (0)
- 811PDMET TUMOR EXPRESSION AND MUTATIONAL ANALYSIS IN BLADDER CANCER PATIENTS (PTS) RECEIVING CABOZANTINIB. (2014) (0)
- The kinetics and reproducibility of 18F-Sodium Fluoride (NaF) PET imaging (2012) (0)
- Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. (2023) (0)
- External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. (2012) (0)
- Impact of lenalidomide on the antiproliferative effect of gemcitabine/carboplatin (GC) and gemcitabine/cisplatin (GP) against urothelial carcinoma (UC) cells in vitro. (2011) (0)
- Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC). (2023) (0)
- Prognostic value of sequential 18F-FDG + Na18F PET/CT (NaF+FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated with cabozantinib/nivolumab +/- ipilimumab (CaboNivoIpi). (2019) (0)
This paper list is powered by the following services:
Other Resources About Andrea Apolo
What Schools Are Affiliated With Andrea Apolo?
Andrea Apolo is affiliated with the following schools:
